ArteraAI and GenesisCare Partner to Provide Precision Cancer Therapy to Patients with Localized Prostate Cancer In Australia

SAN FRANCISCO & SYDNEY–(BUSINESS WIRE)–ArteraAI, the developer of multimodal artificial intelligence (MMAI)-based predictive and prognostic cancer tests, and GenesisCare, one of the leading integrated cancer care providers in Australia, today announced a partnership to help bring AI-based decision making tools to Australia as part of a new clinical trial. The…
Click here to view original post